Sirona CBCT — Verify the Exact Device, Exposure and Report

Sirona CBCT is a brand clue, not an imaging prescription

Sirona is a historic imaging name now used within the Dentsply Sirona portfolio. It does not identify one cone-beam computed tomography unit. A quotation or treatment plan that says only Sirona CBCT, Sirona 3D or German 3D scan leaves open the exact machine, configuration, field of view, acquisition mode, voxel setting, X-ray factors, reconstruction software, reporting pathway and regulatory market.

Current official Dentsply Sirona material includes [Axeos](https://www.dentsplysirona.com/en-gb/discover/discover-by-brand/axeos.html) and [Orthophos S](https://www.dentsplysirona.com/en-al/discover/discover-by-brand/orthophos-s.html) pages. Earlier product names such as GALILEOS, Orthophos XG 3D and some Orthophos SL configurations may still appear in practices, resale listings or old case files. A historic name can be clinically serviceable when lawfully maintained, but an old brochure cannot establish the current configuration, software, quality-control state or suitability for a new examination.

CBCT is an X-ray exposure that creates a three-dimensional dataset. It can answer selected hard-tissue questions that history, examination and lower-exposure imaging cannot answer adequately. It is not a treatment, a routine booking add-on, a screening photograph, proof that an implant is indicated or a substitute for a clinical report.

This page is a neutral device-verification and imaging-decision guide. It does not state that WeCare, a named clinic, dentist, radiologist, imaging centre or intermediary owns, operates, supplies or is authorised for a Sirona device. It does not verify stock, professional registration, facility permission, equipment licensing, calibration, image quality, diagnosis or reporting competence. It does not describe CBCT as harmless, universally low dose, safest, superior or necessary. Those facts require a current physical device, local records, an individual justification and named professional responsibility.

The defensible sequence is clinical question first, justification second, optimised protocol third, complete-volume evaluation fourth and portable handover fifth. A machine name belongs inside that pathway; it cannot replace it.

Build an exact identity record before comparing scans

Start at the rating plate and acquisition record rather than the room photograph. The record should connect the patient and exposure to the exact installed unit without publishing unnecessary device credentials in a public message.

A sticker reading Dentsply Sirona confirms little by itself. It does not show whether a unit is 2D-only or 2D/3D, which optional volumes are enabled, which software acquired the image or whether the machine passed its required tests. Conversely, a software screenshot may show the examination but not the legal identity of the X-ray generator.

Ask for a case-linked acquisition summary containing the necessary identifiers. Do not ask staff to disclose security-sensitive network details or unrelated patient data. The aim is traceability, not a photograph collection.

Distinguish current portfolio pages from installed legacy systems

Dentsply Sirona's regional pages currently present Axeos and Orthophos S as extraoral imaging products. Regional publication does not prove that every model, option or software module is placed on the Turkish market or installed at one facility. Product pages also change more quickly than installed equipment. A device can remain in lawful clinical service after its marketing page changes, provided the local legal, maintenance and quality requirements are met.

For an older system, ask for:

• the exact rating-plate model and serial number;
• the original and current applicable instructions;
• the installed detector and 3D configuration;
• the acquisition and reconstruction software versions;
• service and software-support status;
• acceptance, commissioning and periodic quality-control records;
• the program table used for the actual examination;
• the native export route and a compatible viewer;
• the facility's process for faults, updates and end-of-support notices.

Do not relabel a GALILEOS or Orthophos XG dataset as Axeos because the software now carries a Dentsply Sirona logo. Do not apply a current Axeos field-of-view or voxel table to an older unit. The correct specification is the one for the exact device, market, program and software revision used at exposure.

Age alone does not rank clinical usefulness. A newer unit can be poorly justified, incorrectly positioned or inadequately reported. An older unit can have a documented indication and stable quality-control record. Compare the complete examination pathway rather than a manufacturing year.

Verify the legal manufacturer and current instructions

The March 2025 [Axeos instructions for use](https://www.dentsplysirona.com/content/dam/master/product-procedure-brand-categories/imaging/product-categories/extraoral-imaging/3d-imaging-/ifu/IMG-IFU-Axeos-EN-6730563-2025-03-03.pdf) identify Sirona Dental Systems GmbH, Fabrikstrasse 31, 64625 Bensheim, Germany in the manufacturer information and carry document number 67 30 563 D3644, revision D3644.201.01.04.02. That is strong evidence for the device described by that edition. It is not proof that the same legal-manufacturer line, revision or program set applies to every Sirona-branded unit or market.

The official [Dentsply Sirona Download Center](https://www.dentsplysirona.com/en-us/customer-support/download-center.html) is the starting point for current IFUs, declarations and technical material. Search using the exact product and document identifier. Save the title, language, revision and retrieval date. A distributor brochure, training slide or search-engine excerpt is not a substitute for the applicable instructions.

Before the scan, reconcile:

1. rating-plate identity;
2. local device or facility record where applicable;
3. current market-specific IFU;
4. installed software and enabled programs;
5. acquisition screen;
6. final examination record.

If these disagree, resolve the discrepancy before exposure. A later file rename cannot repair a wrong protocol or missing legal identity.

Start with a justified clinical question, not a CBCT request

The [IAEA Radiation Protection in Dental Radiology, Safety Reports Series No. 108](https://www-pub.iaea.org/MTCD/Publications/PDF/PUB1972_Web.pdf) explains that CBCT can be appropriate when conventional radiography cannot answer the diagnostic question adequately and when the result is likely to affect management or prognosis. That creates a decision test:

• What finding is uncertain after history and examination?
• Which anatomical region contains the uncertainty?
• What non-ionising or lower-exposure information already exists?
• How could the answer change management?
• What happens if the scan is deferred or not performed?
• Which smallest physically collimated volume can include the question with a reasonable margin?
• Which image quality is necessary, rather than merely available?

“Implant package”, “full check”, “digital smile”, “new patient” or “because the machine is here” is not a sufficient clinical question. A responsible request might concern the three-dimensional anatomy of one implant site after the restorative and clinical assessment, suspected complex root anatomy not resolved by two-dimensional imaging, or the location of an impacted tooth when that information could change surgery.

The decision may be not to expose. Previous images, focused intraoral radiographs, panoramic imaging, ultrasound, MRI, conventional medical CT or clinical monitoring can be more appropriate depending on the tissue and question. The practitioner responsible for justification must weigh these alternatives under the law of the exposure jurisdiction.

CBCT is not a population screen or automatic full-mouth record

A broad volume can reveal more anatomy, but “more” is not automatically more useful. It also increases the region requiring evaluation and can include structures outside the referrer's expertise. The European Commission lists [Radiation Protection No. 172](https://energy.ec.europa.eu/topics/nuclear-energy/radiation-protection/scientific-seminars-and-publications/radiation-protection-series-publications_en) as its evidence-based dental CBCT guideline. Its basic principles require patient-specific justification, new information likely to aid management, avoidance of routine repeats, the smallest compatible volume and a clinical evaluation of the entire dataset.

Do not acquire a large craniofacial volume merely to create synthetic panoramic or cephalometric images when a suitable lower-exposure examination could answer the question. Do not scan an asymptomatic traveller so that every future treatment possibility is “covered”. Do not let a promotional bundle convert an optional exposure into a default.

If several genuine questions exist, document them separately. One appropriately selected volume may sometimes address them, but the practitioner should show why its net benefit is greater than targeted alternatives. If a broad volume is used, the report pathway must cover the complete anatomy captured, including incidental findings and limitations.

Separate referrer, practitioner, operator and reporter roles

Names and responsibilities vary by jurisdiction, but the functions should remain visible.

The referrer supplies relevant history, examination findings, prior imaging and the clinical question. The practitioner or other legally entitled justifier decides whether the exposure has sufficient net benefit and authorises it according to local procedure. The operator performs practical aspects assigned within competence: identity checks, pregnancy enquiry where applicable, positioning, protocol selection, exposure and data handling. The reporter or clinical evaluator reviews the entire captured volume and records findings, limitations and actions.

One person may perform more than one role if law, training and employer procedures permit. That does not erase the functions. The [UK guidance to the Ionising Radiation (Medical Exposure) Regulations 2017](https://www.gov.uk/government/publications/ionising-radiation-medical-exposure-regulations-2017-guidance/guidance-to-the-ionising-radiation-medical-exposure-regulations-2017) illustrates the separation: the referrer provides information, the practitioner justifies, the operator owns allocated practical aspects and a clinical evaluation of each exposure is recorded.

UK terminology does not govern a Turkish exposure. Turkey's [Radiology Services Regulation](https://resmigazete.gov.tr/eskiler/2022/04/20220426-13.htm) and the [private oral and dental healthcare-facility regulation](https://resmigazete.gov.tr/eskiler/2022/10/20221006-1.htm), as amended, provide relevant local starting points. Verify current facility and professional requirements directly. Do not turn a foreign title into a Turkish authority claim.

The entire captured volume needs a clinical evaluation

The patient did not receive radiation only in the slices used for implant measurements. Every included voxel belongs to the exposure. The report should therefore account for the entire acquired volume, within the limitations of CBCT and the reporter's competence.

A complete evaluation should identify:

• patient and examination identifiers;
• reason for the scan and relevant history;
• device, date, program and volume;
• adequacy and technical limitations;
• pertinent positive and negative findings;
• incidental findings throughout the captured anatomy;
• uncertainty or need for another modality;
• comparisons with prior images when available;
• recommended clinical correlation or referral;
• reporter identity and report date.

The person planning an implant may not be trained to evaluate paranasal sinuses, cervical spine, airway, skull base or other anatomy included in a large field. That is a reason to arrange appropriate reporting, not to ignore the regions. The reporting pathway should be agreed before exposure, especially for large or non-dento-alveolar volumes.

Automated segmentation, artificial-intelligence flags, nerve tracing and treatment-planning overlays can assist workflow. They do not replace the clinical evaluation or transfer responsibility to software. Retain the unmodified source dataset, the report and any later addendum so a planning annotation is not mistaken for the diagnostic record.

Incidental findings need an ownership and communication pathway

An incidental finding is outside the original clinical question but may still require description, comparison or referral. Possible examples include sinus changes, impacted or supernumerary teeth, bone lesions, calcifications, temporomandibular changes or other anatomy captured by the chosen field. Presence on CBCT does not itself establish a diagnosis, severity or treatment.

Before scanning, the facility should know:

• who will review all anatomy;
• how urgent and non-urgent findings are graded;
• who communicates with the patient and referrer;
• how an addendum is issued if information changes;
• where a recommendation for medical CT, MRI, ultrasound or specialist assessment goes;
• how communication attempts are recorded;
• how a traveller receives the report and images.

Large fields create a larger reporting obligation. Cropping the displayed view after acquisition does not remove anatomy from the exposure or responsibility. A patient should not be reassured that an unreported region is normal, and a generic phrase such as “scan clear” should not replace an anatomical report.

If the report identifies a potentially urgent condition, elective treatment planning should pause until the responsible clinician decides how it affects care. The brand of the machine adds no diagnostic authority.

Field of view must match the question by physical collimation

Field of view, or FOV, is the volume physically exposed and reconstructed. It affects patient dose, scatter, image quality, anatomy captured and reporting workload. The IAEA states that FOV is one of the most important patient-dose determinants and should cover the region of interest with a reasonable margin without exposing regions not needed for diagnosis. It also distinguishes physical tube-side collimation from software cropping after exposure.

The request should specify a region and question, not simply small, medium or large. For example, one molar root question may require a focused dento-alveolar volume; several implant sites across both arches may require a different field; craniofacial planning may require another modality or reporting competence. The smallest button on a machine is not always the right field if it clips the target and causes a repeat. The correct choice is the smallest physically acquired volume that can answer the question reliably for that patient.

Retain:

• intended anatomy;
• chosen program and physical FOV;
• centring or scout evidence where part of the protocol;
• any collimation option;
• reason for a larger-than-minimum field;
• whether the target was fully included;
• any truncation;
• whether a repeat was considered and why it was or was not made.

Do not describe a software crop as a low-volume acquisition.

Axeos metrics belong to exact programs, not to the brand

The 2025 Axeos IFU identifies the following 3D program structure. These figures are device-document facts, not a prescription and not proof of the configuration installed at a facility.

The same IFU contains program-specific dose-area-product information and calculation methods. Do not detach one value from its kV, mA, exposure time, program, field, patient setting and measurement method. Do not present the largest volume or smallest voxel as the machine's one specification.

For the individual examination, record what was actually selected. A brochure statement that a device reaches 80 μm does not show that the patient's scan used VOL2 HD, that this mode was justified or that motion and artefact allowed the expected detail.

Orthophos S metrics require its own exact configuration

The current regional Orthophos S page describes selectable volumes from approximately 5 cm × 5.5 cm to 8 cm × 8 cm, with an optional range up to approximately 11 cm × 10 cm, and states that selected HD imaging can reach 80 μm. The official dated [Orthophos S instructions](https://www.dentsplysirona.com/services/asset/download?path=%2Fcontent%2Fdam%2Fmaster%2Fproduct-procedure-brand-categories%2Fimaging%2Fproduct-categories%2Fextraoral-imaging%2F2d-imaging-%2Fifu%2Farchived%2FIMG-IFU-Orthophos-S-2D-S-3D-S-2D-Ceph-S-3D-Ceph-EN-6678598-2024-08-15.pdf) cover named 2D, 3D and cephalometric configurations and provide technical and program information.

This does not mean every Orthophos S is a CBCT unit. Some installations may be 2D or have different options. “Optional up to 11 × 10” is not evidence that the option is installed, enabled or lawful in one market. A cephalometric arm is another configuration detail, not proof of 3D capability.

Ask the facility to show:

• the full rating-plate model;
• 2D/3D configuration;
• sensor and optional modules;
• available physical volume programs;
• program used for the patient;
• exact software version;
• current IFU for that market;
• quality-control baseline for those modes.

Never transfer Axeos VOL tables to Orthophos S. Never infer a voxel from an image label alone. The case acquisition record controls.

Voxel size is not the same as diagnostic spatial resolution

A voxel is the three-dimensional sampling element in the reconstructed dataset. A smaller nominal isotropic voxel edge can support display of finer structures, but it does not prove that the system resolves anatomy of the same size. Detector performance, focal spot, number of projections, motion, scatter, reconstruction, contrast, noise, metal, patient size, centring and display conditions all contribute.

Do not translate 80 μm into “sees every canal”, “detects every fracture” or a measurement-accuracy promise. A crack can be narrower than a voxel yet influence several voxels, while artefact can mimic or conceal a line. A high-definition mode can increase acquisition burden or patient dose compared with another mode. The practitioner should choose image quality sufficient for the clinical question, not the smallest advertised number.

The record should state:

• exact nominal voxel edge for the selected program;
• mode and reconstruction;
• patient movement or other degradation;
• metal and beam-hardening artefact;
• whether the diagnostic structure is interpretable;
• limitations in the report.

When comparing providers, ask whether the protocol answers the question at an optimised exposure, not whose website prints the smallest number.

Low, standard and HD are protocol names, not universal dose categories

Manufacturer modes such as Low, SD and HD are program-specific labels. They are not comparable across different fields, devices, software revisions or patient settings. “Low Dose” does not mean no risk, and “HD” does not automatically mean clinically better.

A focused high-detail question and a broad surgical question can require different balances. Noise acceptable for gross localisation may be inadequate for a subtle endodontic feature. Conversely, a high-detail protocol may add exposure without changing an implant decision. Patient size and movement risk also matter.

Ask the practitioner to document:

1. the diagnostic task;
2. the selected physical FOV;
3. the selected resolution or mode;
4. patient-size setting and exposure factors;
5. expected image-quality requirement;
6. displayed dose metric;
7. reason a lower-exposure protocol was not adequate, if relevant.

Marketing comparisons that place one low mode beside an unspecified panoramic exposure are incomplete unless fields, diagnostic tasks, dose quantities and measurement conditions are aligned. A mode name cannot be used as personal risk advice.

Dose-area product is not an individual effective-dose number

Dental CBCT devices commonly record or display dose-area product, often expressed as mGy·cm². DAP combines air kerma with irradiated area under the device's measurement method. It supports quality assurance, diagnostic reference-level work and comparison of like protocols. It is not the absorbed dose to every organ, and it should not be relabelled as effective dose.

Effective dose is a population radiation-protection quantity estimated using models and tissue-weighting factors. It is not measured directly by the CBCT unit and is not a prediction of an individual's future health. Converting DAP to effective dose requires assumptions about beam geometry, anatomy, age and methodology. If a numerical risk discussion is needed, it should state the source, units, uncertainty and purpose.

The exposure record should preserve:

• exact DAP or other displayed dose index;
• unit;
• program, FOV and collimation;
• kV and current-time information;
• exposure time;
• patient setting;
• retake status;
• device and software identity.

Compare the actual value with the facility's protocol baselines and applicable diagnostic reference levels under professional oversight. Do not use a low-looking number to bypass justification.

ALARA and ALADA begin after justification

ALARA means keeping exposure as low as reasonably achievable while obtaining the information required. UK law uses language such as as low as reasonably practicable. ALADA, “as low as diagnostically acceptable”, is used in dental discussion to emphasise adequate diagnostic quality. None of these phrases means acquire a scan first and optimise it afterward.

The order matters:

1. establish whether ionising imaging is justified;
2. choose the suitable modality;
3. restrict physical FOV;
4. select sufficient but not excessive image quality;
5. adapt exposure to the patient and task;
6. position carefully to avoid a repeat;
7. evaluate and record the complete result;
8. audit protocols and rejects.

A very noisy scan that cannot answer the question is not optimised if it leads to repetition. A technically beautiful large-volume scan is not optimised when a smaller field or conventional radiograph would have been enough. ALARA is a decision process, not a low-dose logo. ALADA is not a permission to expose without net benefit.

Ask which local protocol, reference level, quality criterion and reject-analysis process supports the chosen examination.

Search for previous imaging before repeating exposure

Previous radiographs, CBCT, medical CT, MRI, reports and treatment records can answer all or part of the question or guide a smaller new acquisition. The requester should identify dates, regions, quality, changes in symptoms and whether the earlier dataset can be imported at native quality.

A repeat can be justified when the old image no longer represents anatomy, does not include the required site, is technically inadequate, cannot answer a new question or when findings could change management. It should not be automatic because a patient changed clinics, travelled, received a new quote or because one software cannot easily open the old file.

Before repeating:

• obtain the prior report;
• request the native DICOM dataset, not screenshots alone;
• verify identity and orientation;
• inspect coverage and artefacts;
• ask whether a new clinical event changes the question;
• document why reformatting or re-reporting is insufficient;
• select a new field only if net benefit remains.

Registration or stitching of old and new datasets can introduce alignment uncertainty. Preserve originals and record any transformation. A comparison view is not proof of biological progression unless acquisition and interpretation limitations are considered.

Pregnancy requires a proportionate, individual enquiry

Pregnancy does not turn every dental X-ray into an automatic emergency or an automatic prohibition. The decision depends on the anatomical field, urgency, expected benefit, alternatives and local procedure. Because dental CBCT targets the head and neck rather than the abdomen or pelvis, fetal exposure pathways differ from abdominal imaging, but that fact should not be converted into a blanket statement about risk.

The referrer and practitioner should receive relevant pregnancy information when known, and the operator should follow the facility's documented enquiry and escalation procedure. If the examination can be deferred without affecting care, deferral may be considered. If it is clinically important, justification and optimisation remain the controlling principles.

Record:

• the clinical question and urgency;
• pregnancy status information volunteered or requested under procedure;
• practitioner decision;
• alternative imaging considered;
• selected field and protocol;
• advice from a medical physics expert when indicated;
• patient information and consent process.

Do not use a brand brochure as pregnancy guidance. Do not demand irrelevant reproductive information. The facility privacy notice and local law govern how sensitive data are collected and retained.

Children need a higher justification threshold and child-specific optimisation

Children have a longer remaining lifetime in which radiation-related stochastic effects could manifest, and they may undergo repeated dental imaging. The IAEA report therefore emphasises paediatric justification and child-adapted equipment and protocols.

CBCT should not be a routine orthodontic record, a cooperation test or a way to synthesise conventional views. The request should explain why history, examination and lower-exposure imaging cannot answer the question, how the result could change management and why the chosen timing matters.

Child-specific planning includes:

• smallest appropriate physical FOV;
• patient-size exposure setting;
• sufficient rather than maximal resolution;
• positioning aids that fit;
• preparation that reduces movement;
• caregiver role under local rules;
• previous-image search;
• complete reporting by a suitably competent person;
• consent or assent processes appropriate to age and law.

If the child cannot remain sufficiently still, motion may erase the intended benefit. A faster mode or alternative examination may be considered, but the device setting must remain tied to the question. Do not repeat merely to obtain a cosmetically perfect volume if the first scan is diagnostically adequate.

Positioning and motion are part of radiation protection

CBCT reconstruction assumes a stable relationship between patient and scanner during projection acquisition. Movement can create double contours, blur, streaks or discontinuities that obscure small anatomy. Positioning errors can clip the target or place metal in an unfavourable path.

Before exposure, remove removable metal where appropriate and explain the need to stay still. Use the device's current positioning instructions, physical supports, light localisers or scout views. Accommodate mobility, tremor, pain, limited opening, gag reflex, wheelchair use and communication needs without improvising outside the IFU.

After acquisition, the operator should check:

• correct patient and side;
• full target inclusion;
• motion;
• truncation;
• detector or reconstruction fault;
• metal artefact;
• whether the question remains answerable.

A repeat needs a new decision. The fact that the scan looks imperfect does not mean another exposure is justified; the fact that a planning software opens it does not mean it is diagnostically adequate. Record why a repeat occurred, adjust the cause and include the repeated exposure in the dose and clinical record.

Metal artefact reduction does not restore missing truth

Implants, crowns, posts, restorations, orthodontic appliances and other radiopaque materials can produce beam hardening, scatter, streaks and dark bands. These effects can obscure cortical boundaries, root surfaces, canals or peri-implant regions and can create features that resemble disease.

Dentsply Sirona pages describe MARS as metal artefact reduction software on selected systems. The IAEA notes limited evidence across current CBCT metal-reduction algorithms and does not treat the presence of such an option as a standalone equipment-selection criterion. An algorithm can change image appearance; it cannot reconstruct anatomy that was never reliably encoded.

The report should identify significant artefact and its effect on the question. Review source reconstructions and alternative settings where appropriate, but retain the original dataset. Do not send only a filtered screenshot. If the question remains unresolved, the practitioner may consider a different view, modality, timing or direct clinical assessment.

Ask whether metal can be removed before imaging, whether the target can be centred away from dense material and whether the selected FOV and trajectory reduce unnecessary artefact. No brand-specific filter establishes a diagnosis.

CBCT grey values are not automatically Hounsfield units or bone quality

Medical multidetector CT can produce calibrated attenuation values under defined conditions. Dental CBCT grey values vary with scanner, protocol, position, field, scatter, reconstruction and artefact. The IAEA advises against using dental CBCT for absolute or relative density estimates based on unstable grey values unless a system demonstrates the required Hounsfield-unit stability.

Therefore:

• do not label a Sirona voxel value as HU without product-specific validation;
• do not classify implant bone quality from a colour map alone;
• do not convert brightness into mineral density;
• do not compare grey values across different scanners or modes as if calibrated;
• do not use software thresholds without documenting their limitations.

CBCT can show dimensions and high-contrast anatomy within its validated performance, but image appearance still requires clinical interpretation. If true quantitative density or soft-tissue characterisation is central, another modality or calibrated method may be needed.

The report should state when artefact or grey-value instability limits assessment. Planning software may use thresholding for segmentation; the segmentation is a derived model, not the original diagnostic evidence.

Measurement accuracy depends on the complete imaging chain

CBCT is used for linear and angular measurements, but a displayed ruler is not an automatic accuracy certificate. Geometric performance depends on device calibration, reconstruction, voxel geometry, patient motion, metal artefact, segmentation, plane orientation, display and landmark selection.

For an implant measurement, record how the cross-sectional plane was aligned, which anatomical boundary was chosen, how uncertainty and a clinical safety margin were handled and whether a radiographic guide or merged surface scan was used. For endodontics, a distance on CBCT does not replace clinical working-length methods. For orthodontics, a three-dimensional landmark can have observer and segmentation variability.

Quality assurance should test geometric accuracy using appropriate phantoms and action levels. The current device manual and local medical-physics programme define the method. A manufacturer nominal voxel size is not the result of the facility's most recent test.

When a measurement controls an irreversible step, the treating professional should connect it to examination, other records and clinical judgement. Save relevant planning views and versioned derived files, while preserving the source DICOM and report.

Implant planning needs a restorative question, not a routine scan

CBCT may help assess three-dimensional anatomy for implant planning, including selected bone dimensions and proximity to relevant structures. It cannot decide whether a tooth should be removed, whether an implant is preferable to preservation or a bridge, whether disease is controlled, whether the patient accepts maintenance or whether the proposed prosthesis is feasible.

Before imaging, define:

• missing or failing tooth diagnosis;
• preservation and non-implant alternatives;
• periodontal and endodontic status;
• intended restoration and emergence;
• number and location of candidate sites;
• clinical ridge and soft-tissue findings;
• prior images;
• exact anatomical question that needs 3D information.

After imaging, connect findings to the restorative plan. A nerve tracing, implant-library cylinder or surgical-guide overlay is a planning aid. It does not confirm nerve location, implant system compatibility, drill accuracy or surgical result. Merged intraoral scans can misregister; check landmarks and retain versions.

If an incidental lesion, sinus finding or unexpected anatomy appears, resolve it before proceeding. “CBCT approved” is not a diagnosis. The report, clinical examination and informed consent should remain distinct from the machine output.

Endodontic use should be selective and usually focused

The IAEA lists examples where small-FOV, higher-spatial-resolution CBCT might be considered when conventional imaging is inadequate: complex anatomy, suspected perforation, extensively obliterated canals, resorption, selected trauma or image-guided procedures. That is not a recommendation to scan every root-canal case.

Two-dimensional radiographs from different angles, clinical tests, magnification and treatment history often remain central. CBCT has limited soft-tissue contrast, and root fillings, posts and crowns can create severe artefact. A high-detail mode may increase exposure and motion sensitivity.

The request should name one unresolved question and tooth or region. Select the smallest field that includes the target with a reasonable margin. The report should address the full captured volume, not only the suspected canal. If a fracture is suspected, state that artefact can mimic or obscure lines and that a negative scan does not exclude every fracture.

Do not use a Sirona 80 μm claim as a diagnostic promise. The actual VOL program, patient motion, restorations and reconstruction determine interpretability. The endodontist still owns diagnosis and treatment decisions.

Orthodontic CBCT should not be automatic

A three-dimensional dataset can support selected questions involving impacted teeth, craniofacial anomalies, clefts, asymmetry, resorption risk, airway or surgical planning. It should not be acquired routinely because an orthodontic package includes 3D, because software can generate cephalometric views or because a patient is at the start or end of treatment.

The IAEA report notes lack of patient-benefit evidence for routine orthodontic CBCT and states that acquisition solely to synthesise panoramic or cephalometric views is inappropriate. Children and adolescents require especially careful justification.

The record should show:

• clinical and conventional imaging findings;
• specific uncertainty;
• how 3D information may change management;
• child-specific risk consideration;
• smallest compatible FOV;
• resolution needed;
• full-volume reporting;
• repeat-imaging threshold.

Airway dimensions on a standing dental CBCT are affected by posture, tongue, breathing phase and wakefulness. They do not diagnose sleep apnoea. TMJ osseous appearance does not show disc position like MRI. Software analyses are derived measurements with their own validation and uncertainty.

Impacted teeth, TMJ and sinus questions need anatomical boundaries

For an impacted tooth, CBCT may clarify three-dimensional position, root relationship, resorption or surgical anatomy when conventional views are insufficient. The scan does not itself establish that removal, exposure, traction or observation is preferable. That decision uses symptoms, pathology, age, tooth value, surgical risk and alternatives.

For the temporomandibular joint, CBCT primarily depicts osseous structures. It does not directly show the disc or many soft-tissue conditions; MRI may be relevant when internal derangement is the question. A large field should not be selected merely because both joints can fit unless the bilateral question is justified.

Paranasal sinus changes can be visible in dental CBCT, but the modality, field and reporter must be appropriate. Dental findings do not replace ear, nose and throat or medical assessment when symptoms or soft tissue require it.

Write the intended structure and limitation into the request. A broad “check everything” instruction is not a reporting plan. If captured anatomy extends beyond the intended dento-alveolar region, arrange the competence needed for complete evaluation.

CBCT has important soft-tissue and pathology limits

Dental CBCT is designed mainly for high-contrast hard-tissue imaging. It has poorer soft-tissue contrast than conventional medical CT and MRI and can be affected by scatter and truncation. The European CBCT principles advise using medical CT or MRI when soft-tissue evaluation is likely to be required.

This matters for:

• suspected soft-tissue tumour;
• deep infection spread;
• airway or vascular questions;
• salivary-gland disease;
• temporomandibular disc assessment;
• neurological symptoms;
• trauma extending beyond the dento-maxillofacial field;
• lesions whose internal characterisation or extent is uncertain.

CBCT can reveal a bone change that triggers further investigation without identifying its nature. Do not advertise incidental visibility as comprehensive cancer screening. Do not reassure a patient that tissues outside the modality's capability are normal.

The report should describe what is seen, what is not evaluable and what additional clinical or imaging assessment is recommended. Urgent symptoms take priority over travel or elective treatment scheduling.

A decision-grade referral contains more than a treatment label

The referrer should provide enough information for justification and reporting. A useful referral includes:

• patient identifiers;
• relevant symptoms, duration and site;
• examination findings;
• working differential or uncertainty;
• precise clinical question;
• prior imaging dates and access;
• relevant treatment and trauma history;
• pregnancy information where relevant and lawful;
• mobility or movement considerations;
• proposed management that could change;
• requested region, while leaving protocol selection to the entitled practitioner.

“Implants”, “root canal”, “orthodontics” or “3D scan” is inadequate. If the imaging centre receives insufficient information, it should obtain clarification rather than invent a question from a sales booking.

The report should answer the question but also record important findings elsewhere in the captured volume. If the clinical question changes after examination, update the referral and justification before exposure. Retain both original and revised versions where required.

For cross-border cases, translation should preserve clinical meaning. A coordinator can transmit records but should not create a diagnosis or authorise radiation unless independently entitled under local law.

The acquisition record should be reproducible without exposing private data

A complete case record links the exposure to patient, device, protocol and professionals. It should normally include:

• request and justification or authorisation;
• patient identity check;
• exposure date and time;
• exact device and serial or internal asset identifier;
• acquisition software version;
• program and physical FOV;
• region and collimation;
• voxel or resolution mode;
• kV, mA or mAs and exposure time;
• displayed DAP or other device metric with units;
• positioning aids and relevant deviations;
• repeat or reject status;
• operator;
• dataset identifier;
• clinical evaluation and reporter;
• communication of significant findings.

Not every item belongs on a patient-facing invoice, but it should remain traceable within the regulated record. The patient handover can use a device summary rather than exposing staff logins, network paths or other patients.

If the acquisition record says only 3D scan, future clinicians cannot compare dose, judge coverage or locate the correct viewer. If an exported folder contains DICOM but no report, the clinical-evaluation duty remains unresolved.

Acceptance testing, calibration and quality assurance are separate

Manufacturer installation is not the end of quality control. A CBCT facility needs a documented programme covering acceptance or commissioning, baseline values, routine constancy checks, patient-dose assessment, clinical image quality, rejects, display conditions and corrective action under local law and medical-physics advice.

The UKHSA-hosted [guidance on dental CBCT use](https://www.gov.uk/government/publications/dental-cone-beam-computed-tomography-safe-usage) and the [EFOMP–ESTRO–IAEA quality-control protocol summary](https://researchportal.ukhsa.gov.uk/en/publications/quality-control-in-cone-beam-computed-tomography-cbct-efomp-estro/) describe areas such as radiation output, uniformity, geometric precision, noise, low-contrast and spatial resolution using phantoms and defined action levels.

Ask for confirmation that the exact installed modes used clinically lie within the facility's current QA programme. A service sticker alone does not show image-quality or dose-constancy results. A phantom image alone does not show that overdue corrective work was completed.

When a value exceeds an action level or image quality deteriorates, the responsible team should investigate, restrict affected modes when appropriate, correct the fault and document return to clinical use. Patients do not need confidential engineering detail, but they may reasonably ask how the facility verifies continuing performance.

Reject analysis protects against avoidable repeats

Rejected and repeated images should be reviewed as a system, not blamed automatically on a patient. Categories can include positioning, movement, wrong patient or region, clipped anatomy, incorrect program, exposure choice, detector fault, reconstruction failure, software transfer error or inadequate referral.

The quality programme should record:

• reason for rejection;
• whether an additional exposure occurred;
• operator and device;
• program and field;
• contributing factors;
• corrective action;
• trend over time.

A repeat rate by itself does not show quality because case mix and definitions vary. The goal is to identify preventable causes and improve referral, training, positioning, protocols, maintenance and software workflow.

For an individual, a failed planning export is not a reason to repeat a diagnostically adequate exposure. Recover the native dataset, correct software access or export it in a supported format. If a retake is proposed, require a fresh justification explaining why existing information cannot answer the question.

Do not promise “no retakes” based on automatic positioning. Positioning aids may reduce some errors; they do not remove movement, anatomy, protocol or operator factors.

Maintenance, repair and software changes need controlled records

Hardware service, detector replacement, X-ray tube work, calibration, software upgrade and reconstruction changes can affect performance or compatibility. The facility should follow the applicable IFU, service instructions, local rules and medical-physics advice, then perform the checks required before clinical return.

Retain:

• fault description;
• service provider and date;
• components or software changed;
• calibration and verification performed;
• QA results;
• modes released for use;
• unresolved limitations;
• version and backup status.

Do not assume a dealer visit equals regulatory quality assurance. Do not assume a software update is merely cosmetic. Dentsply Sirona's current Sidexis 4 materials show version-dependent functions and installation requirements. An export or planning workflow tested on one version may change after an upgrade.

If a legacy unit loses manufacturer support, the responsible facility should document how parts, cyber security, software compatibility, performance testing and legal obligations are managed. A functioning power switch is not evidence of continuing clinical conformity.

Software identity matters from acquisition to report

Sidexis is a product family as well as a familiar name. Record the exact version used for acquisition, reconstruction, display, export and planning. Sidexis XG, Sidexis 4, Sidexis iX, DS Core and SICAT modules have different functions and should not be merged into one label.

The current [Sidexis 4 product page](https://www.dentsplysirona.com/en-us/discover/discover-by-brand/sidexis-4.html) describes management of 2D and 3D images and collaboration. Current regional download material identifies Sidexis 4.4, while system requirements and plug-ins remain version dependent. A current marketing page does not establish which release acquired an old scan.

The record should distinguish:

• acquisition workstation software;
• reconstruction version;
• diagnostic viewer;
• optional planning module;
• cloud or sharing platform;
• third-party viewer;
• derived STL, surface or guide file.

Filters, windowing, annotations, nerve traces, segmentation and implant overlays are derived displays. They should not overwrite the source dataset. If a report was made in one viewer and the recipient sees another, confirm that native resolution, orientation, bit depth and essential tools remain available.

DICOM export should preserve the native diagnostic dataset

DICOM is a standard for medical-image information and exchange, not one file extension and not an automatic guarantee of interoperability. The [DICOM Standard](https://www.dicomstandard.org/current) defines objects, attributes and transfer structures. Manufacturer conformance statements describe which services a particular implementation supports.

Dentsply Sirona's [Sidexis 4 with SIDICOM RM conformance statement](https://www.dentsplysirona.com/content/dam/master/product-procedure-brand-categories/imaging/product-categories/software/SIDEXIS4_DICOM_conformance_statement_V2.0.pdf.coredownload.pdf) is dated and version-bounded. It demonstrates why the exact plug-in and software version matter. The IAEA recommends third-party CBCT export as an axial stack at native resolution and bit depth in accordance with DICOM, avoiding quality loss during multiplanar reconstruction.

Before exposure, ask whether the handover includes:

• full native DICOM dataset;
• DICOMDIR or supported folder structure where applicable;
• report;
• dose and protocol summary;
• orientation and patient identifiers checked;
• compatible viewer or clear import instructions;
• secure delivery method;
• checksum or completeness verification for large transfers.

JPEG screenshots, a screen recording, a proprietary planning file or a printed cross-section are useful illustrations but not replacements for the native volume.

Test portability before leaving, not after a complication

“We can send the scan” is not enough. A patient travelling home should know what will be sent, in which format, by whom, through what secure channel and whether the receiving professional can open it.

A practical handover test is:

1. export the native dataset;
2. retain the report and protocol summary;
3. open the export on a separate supported workstation or viewer;
4. verify patient, laterality, slice count, orientation and full volume;
5. confirm no unintended downsampling;
6. transfer through an agreed secure route;
7. obtain receipt from the local clinician when clinically important.

Cloud links can expire, require country-specific accounts or allow only browser views. Proprietary viewers can fail on a different operating system. A DICOM folder can be incomplete if one subdirectory is omitted. Plan before travel and keep an encrypted backup according to local policy.

The receiving clinician may need the source images and report, not the implant-planning screenshot. Data access does not force another professional to accept clinical responsibility; agree that separately.

Imaging data are health data, not ordinary holiday files

CBCT datasets contain identifiers and detailed health information. DICOM metadata can include name, birth details, examination identifiers, facility and device information even when the images look anonymous. Email, consumer messaging and portable media create confidentiality, misdirection, malware and loss risks.

The facility should identify the data controller, purposes, recipients, retention, cross-border transfer basis, access process and breach contact under applicable law. Turkey's personal-health-data framework and KVKK requirements apply to Turkish processing; UK GDPR or EU GDPR may apply to relevant UK or EU controllers. The [EU GDPR text](https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1681893754368&uri=CELEX%3A32016R0679) treats health information as protected personal data and provides access rights, but it should not be presented as the governing law for every Turkish facility.

De-identification for teaching or a second opinion requires more than deleting the visible name. Metadata, dates, facial surfaces and linked planning files may permit re-identification. Use documented technical and organisational controls.

Ask for a clinical copy through the facility's lawful access route. Do not post the entire dataset to a public file host merely because it is too large for email.

The report and the dataset answer different needs

The dataset lets an appropriately equipped professional inspect the volume. The report records the clinical evaluation, findings, limitations and actions. One does not replace the other.

A report should not consist only of “suitable for implants”, “no contraindication” or screenshots with measurements. It should identify the indication, coverage, technical adequacy, anatomy, findings, incidental observations, comparison and uncertainty. Treatment decisions remain with the treating professional after correlation with history and examination.

A dataset without a report shifts an unplanned reporting burden to the recipient. A report without source data limits second review, planning and comparison. For a traveller, obtain both before irreversible treatment when CBCT findings materially affect the plan.

If another reporter issues a second opinion, preserve both reports and identify which dataset and version each reviewed. Differences can reflect interpretation, clinical information or image limitations. They should be reconciled rather than hidden by replacing the first PDF.

Consent and patient information should be exposure specific

Consent for treatment and the legal justification of an X-ray exposure are related but not identical. A patient can agree to a scan that the practitioner should not authorise, and refusal does not permit treatment staff to conceal the effect on planning.

Patient information should explain in plain language:

• the clinical question;
• why CBCT rather than another option is proposed;
• ionising-radiation benefit and risk;
• selected anatomical field;
• important limitations;
• possibility of incidental findings;
• who reports the scan;
• how results may change or not change treatment;
• data access and sharing;
• what happens if the scan is declined.

Avoid claims that the exposure is risk free, completely safe, necessary for everyone or certain to produce a diagnosis. Avoid comparisons using background radiation or flights without stating assumptions and dose quantity.

If the field or protocol changes materially after the discussion, update the explanation and authorisation. If the scan is part of research, teaching or software development, separate those purposes and permissions from clinical care.

The quotation should itemise imaging and reporting

A decision-grade quote separates:

• clinical examination and referral;
• CBCT acquisition;
• exact anatomical field or protocol category;
• clinical evaluation or formal report;
• specialist reporting if applicable;
• DICOM export;
• viewer or media;
• cloud or secure-transfer service;
• repeat policy;
• second opinion;
• data retention or access charges where lawful;
• exclusions and change rules.

Do not infer a price from this guide. Do not accept an unspecified “3D included” line that hides whether the scan has a report, whether export is native or whether another facility performs the exposure. If imaging is outsourced, identify who is the legal provider, controller, justifier, operator and reporter.

Treatment and imaging costs should remain separable so a patient can obtain the dataset and report even if they decline the proposed dentistry, subject to lawful terms. Travel, accommodation and transport are non-clinical services and should not be used to make an exposure appear complimentary or mandatory.

Any new field, repeat or specialist report should follow a documented clinical decision and updated costs before it occurs, except where urgent law and care require another process.

Cross-border travel should follow the imaging question

A flight date is not a radiological indication. Obtain and review existing images before travel where possible. If new CBCT is likely to be needed, clarify the question, timing, reporting and export pathway in advance without promising that the exposure will occur.

Allow enough clinical flexibility for:

• examination before justification;
• clarification of previous records;
• reporting of the entire volume;
• further imaging if another modality is indicated;
• discussion of incidental findings;
• revision of a treatment plan;
• transfer to a local professional.

Do not schedule irreversible treatment immediately after an unreported scan merely because the itinerary is short. Do not repeat a scan at home because the overseas file was not exported correctly. Data workflow is part of clinical planning.

Before leaving, verify the dataset and report open successfully, the local contact receives them and urgent communication details work. A coordinator can organise transfer but cannot interpret the image unless independently qualified and responsible under the applicable law.

Local handover should be agreed before exposure abroad

The home clinician may be asked to assess pain, infection, a missed finding, implant complications or future comparisons. Ask in advance whether they can view the dataset, what viewer they use and whether they accept reporting or treatment responsibility. They may reasonably require a formal report or another modality.

The handover pack should contain:

• referral and clinical question;
• acquisition summary;
• exact device and software;
• physical FOV and protocol;
• dose metric with units;
• full native DICOM;
• clinical report and addenda;
• derived planning files clearly labelled;
• relevant treatment plan;
• contact for the imaging facility and reporter;
• privacy-compatible transfer instructions.

If the home clinician cannot open the proprietary data, request standards-based export before departure. If they identify a concerning feature, provide access to the original reporter and treating professional. Cross-border care needs explicit ownership; it should not depend on a messaging thread.

Urgent symptoms override device comparison

CBCT is not an emergency service. Severe or increasing dental pain, spreading swelling, fever, uncontrolled bleeding, significant trauma, new facial numbness or rapidly worsening symptoms need timely local clinical assessment. Difficulty breathing or swallowing, major facial swelling, eye involvement or serious injury can require emergency care.

Do not delay because an overseas scan is booked or because a Sirona device is preferred. The urgent professional decides which examination, if any, is appropriate. Medical CT, MRI, ultrasound, focused dental radiographs or no immediate imaging may be chosen.

If a report reveals a potentially serious incidental finding, ensure that communication and referral occur through the named clinical pathway. A portal notification is not enough when the facility's procedure requires direct escalation.

Bring prior images and reports when seeking care, but do not attempt self-diagnosis from a 3D viewer. Filters and colour maps can make normal structures look alarming or conceal pathology.

Red flags that justify pausing the scan

Pause for clarification when:

• Sirona is the only model description;
• no clinical examination or question exists;
• CBCT is routine for every new patient or package;
• the largest field is selected by default;
• software cropping is described as reduced exposure;
• a nominal voxel is presented as diagnostic certainty;
• Low Dose is described as no risk;
• no previous-image search occurred;
• no named person owns justification;
• no one will evaluate the full volume;
• the reporter is unidentified;
• device, software or IFU versions conflict;
• QA, service or fault questions cannot be routed to a responsible person;
• the export is screenshots only;
• a report costs unexpectedly extra after exposure;
• the patient cannot receive the native data;
• an incidental finding has no communication pathway;
• the itinerary prevents review before irreversible care;
• another exposure is proposed only because files were not transferred.

One unresolved administrative detail may be fixable. Several unresolved clinical and governance gaps justify deferral or an independent opinion. The machine brand cannot cure them.

Sirona CBCT verification worksheet

Use this worksheet before exposure:

Clinical question

• What finding remains uncertain?
• What examination and previous images exist?
• How could CBCT change management?
• Could a lower-exposure or non-ionising option answer it?
• Is the timing clinically relevant?

Device and protocol

• Exact model, type and serial or asset identifier?
• Legal manufacturer on the rating plate?
• Current market-specific IFU and revision?
• 2D/3D configuration and enabled options?
• Acquisition and reconstruction software versions?
• Physical FOV, region and collimation?
• Mode and nominal voxel?
• kV, current-time, exposure time and DAP?

Governance

• Named referrer?
• Named practitioner or justifier?
• Named operator?
• Named reporter?
• Whole-volume evaluation?
• Incidental-findings route?
• Facility and device permissions verified through current official channels?

Quality

• Current acceptance and routine QA programme?
• Relevant modes tested?
• Fault or service restrictions?
• Motion, truncation or metal artefact?
• Repeat reason and corrective action?

Handover

• Full native DICOM?
• Report and addenda?
• Protocol and dose summary?
• Secure transfer?
• Independent opening test?
• Local receiving professional?
• Privacy notice and access route?

If the answers remain vague, the imaging proposal is not yet decision grade.

Primary official sources used here

Product identity and exact program figures come from the current Dentsply Sirona Axeos page, March 2025 Axeos IFU, current Orthophos S regional page, dated official Orthophos S IFU, Sidexis 4 page, Dentsply Sirona download centre and the version-bounded Sidexis DICOM conformance statement.

Radiation-protection and governance boundaries come from the IAEA Safety Reports Series No. 108, the European Commission Radiation Protection series entry for No. 172, UK government IR(ME)R guidance, UKHSA dental CBCT material, the EFOMP–ESTRO–IAEA quality-control protocol summary and current Turkish radiology and oral-health facility regulations. The DICOM Standard supports the data-format discussion, while applicable Turkish, UK or EU privacy law depends on the controllers and transfers involved.

Every source has a limited job. A manufacturer document describes its specified device; it does not justify an individual exposure. A radiation guideline does not prove one clinic complies. A facility record does not interpret anatomy. A DICOM export does not equal a report. Recheck documents, laws and software for the actual market and date.

Final rule: verify question, exposure and evaluation separately

A defensible Sirona CBCT examination has three connected records.

The question record contains history, examination, prior images, uncertainty, alternatives and patient-specific justification. The exposure record contains exact device, software, physical FOV, program, voxel, factors, dose metric, positioning, operator and QA context. The evaluation record contains the complete-volume report, limitations, incidental findings, communication, native dataset and local handover.

If one record is missing, the other two cannot fill the gap. A famous machine cannot justify radiation. A low-looking DAP cannot make an inadequate image useful. A planning screenshot cannot replace a report. A report cannot prove the machine passed QA. Verify each layer before relying on the scan for irreversible care.

What the product name does — and does not — tell you

Sirona CBCT is a Dentsply Sirona dental cone-beam CT device and software family. The name can help a patient identify a product family, but it does not establish the diagnosis, the exact model selected, the competence of a treating professional or the quality of the finished treatment. Product ranges, indications and local availability can change. A current manufacturer instruction for use and the legal market status in the country of treatment take priority over a marketing page.

This page is a research guide. It is not a statement that WeCare, a particular clinic or an event clinician stocks or uses Sirona CBCT. Availability must come from the named treating provider. If a quotation uses only a broad phrase such as “premium material”, ask for the manufacturer, product family and reference before accepting the plan.

Manufacturer information worth checking

• The March 2025 Axeos IFU identifies Sirona Dental Systems GmbH and exact VOL1–VOL4 program, field and voxel data; those specifications must not be transferred to another model.
• Current regional Dentsply Sirona pages also present Orthophos S, but installed 2D/3D, cephalometric, field and software options must be verified from the rating plate, configuration and applicable IFU.
• Dentsply Sirona, Sirona, Axeos, Orthophos, Sidexis and SICAT identify different corporate, device or software layers; none alone proves the complete examination pathway.
• Current market status, facility authority, device licensing, operator entitlement, quality control and reporting competence require separate verification in the exposure jurisdiction.

These points describe the product family at a general level. They are not a recommendation for a particular mouth and they should not be extended to a different line carrying a similar brand name. Begin with history, examination, previous images and one management-relevant clinical question. A legally entitled practitioner then decides whether CBCT has sufficient net benefit, selects the smallest compatible physical field and sufficient image quality, and ensures that the complete acquired volume will be evaluated and handed over.

Questions for the named provider

Ask the professional responsible for treatment to answer these points in writing:

1. What is the exact manufacturer, product family, model or material grade proposed?
2. What clinical finding makes that selection appropriate for this case, and what alternatives were considered?
3. Who is the legal treating provider and who will perform each clinical or laboratory stage?
4. Which current instruction for use, contraindications and local regulatory status apply?
5. What reference, lot, batch or other traceability record will be retained and shared where the device permits it?
6. Which components, cements, abutments, membranes, gels or accessories are included, and are they compatible?
7. What follow-up is required, who is responsible after travel, and which costs are excluded from the quotation?

Product verification, evidence and traceability boundaries

Manufacturer pages and IFUs describe exact devices and programs; they do not justify a patient exposure, prove one installed configuration, demonstrate current QA or establish what was selected. Case evidence must connect request, justification, rating plate, software, acquisition factors, displayed dose metric, complete-volume report and native dataset.

Useful evidence may include a photograph of unopened labelled packaging before use, the product label, an implant or device record, a laboratory prescription, an invoice identifying the exact material, and the treating provider's signed notes. The appropriate record depends on the product. A logo on a website, a stock photograph, an unlabelled box or a verbal statement is not equivalent to case-specific traceability.

How to compare alternatives fairly

Compare imaging pathways by clinical question, alternatives, prior-image search, exact device and software, physical FOV, protocol and dose record, positioning, QA, reporter competence, complete-volume evaluation, native DICOM portability, privacy, itemised scope and local follow-up. Do not rank services by brand, nominal voxel or mode name alone.

Compare like with like: indication, exact product, compatible components, laboratory design, operator responsibility, maintenance, staged visits and written exclusions. Do not compare a named product in one quotation with an unspecified category in another. Brand recognition cannot remove biological uncertainty, and no material choice can promise a clinical outcome.

Assessment comes before the brand

A responsible plan starts with medical and dental history, examination and appropriate imaging. Implant decisions can depend on bone, soft tissue, bite, hygiene, smoking, medication and restorative space. Ceramic decisions can depend on remaining tooth tissue, preparation design, opposing teeth and laboratory workflow. Whitening decisions require screening for decay, gum disease, sensitivity and existing restorations. Endodontic and imaging tools are parts of a broader diagnostic or treatment process, not substitutes for professional judgement.

Before paying, request a dated, itemised written plan naming the treating provider, the proposed product, alternatives, material records, visit stages, aftercare responsibilities and financial terms. If the final assessment changes the product or procedure, ask for the reason and revised quotation before treatment proceeds.